In a Lewis lung 2 (LL/2) syngeneic lung cancer mouse model, where a combined triple blockade targeting VEGFR by Vatalanib, ANG-2 by BI-836880, and PD-1 by RMP1-14 was used, the authors have shown improved in vivo antitumor efficacy (11). This evidence concerns the gene KDR and lung carcinoma.